Open Medicine Foundation announces the launch of a new center to advance ME/CFS medical education in partnership with Bateman Horne Center!
The overarching goal of RASPBERRY-ME project is the characterization of the biomolecular signature of Myalgic Encephalomyelitis using Label-free Raman Spectroscopy (RS) and machine learning models.
The purpose of this study is to capture a post-COVID-19 infected population willing to participate in phenotyping studies early in the post-COVID-19 illness progression, with an aim of providing targeted effective therapies and preventing the onset and progression of ME/CFS.
The primary goal of this project is to complete our comprehensive analysis of the genome, methylome, miRnome, and their interactions in order to fill the gaps in our understanding of ME/CFS pathophysiology and to identify clinically useful biomarkers.
The REMEDIAL project continues the work commenced with MAESTRO and will lead to a better understanding of the molecular mechanisms underlying ME/CFS pathophysiology, the persistence and variability of the symptoms, and will contribute to the identification of targets and therapeutic agents for intervention.
Metadescription: Ron Davis discusses how DNA & RNA technology is being developed at Stanford to advance research into ME/CFS, Long COVID, and related diseases.
Robert Phair, PhD gives a video update on the Itaconate Shunt Hypothesis for ME/CFS, a study in collaboration with Christopher W. Armstrong, Ron Davis, PhD, and Ron’s team at Stanford.
NEW Update from Ron Davis! The Itaconate Pathway Today, we are delighted to share the first in a series of research updates from Ronald W. Davis, PhD, Chair of OMF Scientific Advisory Board & Director of the OMF supported ME/CFS Collaborative